Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Buy now fake rolex


Extra reg hurdle for AZ vax

Posted 22 December 2020 AM

AstraZeneca's Covid vaccine is one step closer to commercial supply in Australia with the Office of the Gene Regulator (OGTR) completing its initial risk assessment of the company's proposed activities, saying the GM vaccine "poses negligible risk."

As the activities which includes the import, transport, storage, and disposal of AZD1222 are classified as Dealings involving Intentional Release (DIR) of genetically modified organisms into the Australian environment, the OGTR's approval, along with TGA registration are required before the vaccine can be distributed.

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here

Top of the Hill
Pitfalls may plague NMP review
With an election in play, will it arrive too late?
Approvals Action
First copy of Halaven ticked
Along with other generics of already PBS-listed drugs